Cortexyme Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Quince Therapeutics Inc (QNCX)
Quince Therapeutics Inc stock price live, this page displays NASDAQ QNCX stock exchange data. View the QNCX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Quince Therapeutics Inc real time stock price chart below.
What Is the Quince Therapeutics Inc Stock Price Today?
The Quince Therapeutics Inc stock price today is 32.140.
What Is the Stock Symbol for Quince Therapeutics Inc?
The stock symbol for Quince Therapeutics Inc is "QNCX."
What Stock Exchange Does Quince Therapeutics Inc Trade On?
Quince Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Quince Therapeutics Inc a Good Stock to Buy?
Determining whether Quince Therapeutics Inc, or any stock, is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the QNCX quote. (ISIN: US22053A3059)
What Is the Quince Therapeutics Inc Stock Price Today?
The Quince Therapeutics Inc stock price today is 32.140.
What Is the Stock Symbol for Quince Therapeutics Inc?
The stock symbol for Quince Therapeutics Inc is "QNCX."
What Stock Exchange Does Quince Therapeutics Inc Trade On?
Quince Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Quince Therapeutics Inc a Good Stock to Buy?
Determining whether Quince Therapeutics Inc, or any stock, is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the QNCX quote. (ISIN: US22053A3059)
32.140
-0.010(-0.03%)
Real-time Data·
Fair Value
An estimate of a Quince Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
31.750
32.960
52 wk Range
3.660
909.980
QNCX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Quince Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
31.75032.960
52 wk Range
3.660909.980
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
QNCX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Quince Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
77.200
Upside
+140.20%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Form 8K Quince Therapeutics Inc For: 14 August- Investing.com
Form PRE 14A Quince Therapeutics Inc For: 1 August- Investing.com
- Cortexyme Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Form 8K Quince Therapeutics Inc For: 17 August- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Analyst Ratings
5 Buy
2 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 77.200
(+140.20% Upside)
Earnings
Latest Release
Aug 14, 2026
EPS / Forecast
-12.31 / -9.40
Revenue / Forecast
-- / --
Compare QNCX to Peers and Sector
Metrics to compare | QNCX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipQNCXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.4x | −2.8x | −0.4x | |
PEG Ratio | 0.00 | −0.05 | 0.00 | |
Price/Book | −0.9x | 3.4x | 2.6x | |
Price / LTM Sales | - | 14.2x | 3.1x | |
Upside (Analyst Target) | 118.5% | 105.4% | 49.0% | |
Fair Value Upside | Unlock | 6.5% | 7.1% | Unlock |
Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company’s lead asset candidature comprises eDSP, which is in Phase 3, for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient’s own red blood cells, as well as consist of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising kit medical devices, syringe kit, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Quince Therapeutics (QNCX) Stock Price Today?
The Quince Therapeutics stock price today is 32.140 USD.
What Stock Exchange Does Quince Therapeutics Trade On?
Quince Therapeutics is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Quince Therapeutics?
The stock symbol for Quince Therapeutics is "QNCX."
What Is the Quince Therapeutics Market Cap?
As of today, Quince Therapeutics market cap is 32.690M USD.
What Is Quince Therapeutics's Earnings Per Share (TTM)?
The Quince Therapeutics EPS (TTM) is -51.806.
When Is the Next Quince Therapeutics Earnings Date?
Quince Therapeutics will release its next earnings report on Nov 18, 2026.
From a Technical Analysis Perspective, Is QNCX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Quince Therapeutics Stock Split?
Quince Therapeutics has split 2 times.
How Many Employees Does Quince Therapeutics Have?
Quince Therapeutics has 38 employees.
What is the current trading status of Quince Therapeutics (QNCX)?
As of Sep 03, 2026, Quince Therapeutics (QNCX) is trading at a price of 32.140 USD, with a previous close of 32.150 USD. The stock has fluctuated within a day range of 31.750 USD to 32.960 USD, while its 52-week range spans from 3.660 USD to 909.980 USD.
What Is Quince Therapeutics (QNCX) Price Target According to Analysts?
The average 12-month price target for Quince Therapeutics is 77.200 USD, with a high estimate of 98 USD and a low estimate of 68 USD. 5 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +140.20% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.